Skip to search formSkip to main contentSkip to account menu

ARGX-111

Known as: Anti-c-Met Monoclonal Antibody ARGX-111 
A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.
e14016Background: ARGX-111 is a therapeutic antibody candidate combining three independent MoA: i. blockade of HGF-dependent and… 
2016
2016
Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis
Several lines of experimental evidence suggest that Hepatocyte Growth Factor (HGF) and its receptor MET play an important role in… 
2015
2015
A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
2580 Background: Dysregulation of the tyrosine kinase receptor c-Met, is associated with tumorigenesis, metastasis and… 
2015
2015
P7.02The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis
ABSTRACT Background: Signalling through MET, the hepatocyte growth factor (HGF) receptor, plays a key role in tumor progression… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)